Kersten Dirk 4

What Happened Kersten Dirk, identified as a director, disposed of 263,962 shares of Dyne Therapeutics (DYN) in sales executed June 22–23, 2026, netting approximately $5,464,612. The sales were reported on a Form 4 filed June 24, 2026, and were executed under a Rule 10b5‑1 trading plan adopted by ForDyne B.V.

Key Details

• Transaction dates and reported weighted-average prices:
  • 2026-06-22: 190,676 shares sold at a weighted avg price of $20.57 (range $20.13–$20.97). (Footnote F2)
  • 2026-06-23: 71,629 shares sold at a weighted avg price of $21.04 (range $20.45–$21.44). (Footnote F5)
  • 2026-06-23: 1,657 shares sold at a weighted avg price of $21.47 (range $21.45–$21.495). (Footnote F6)
• Total: 263,962 shares sold for about $5.46 million.
• Shares were held directly by ForDyne B.V.; the filing discloses complex institutional ownership and that Kersten is a partner/committee member in entities (Forbion-related) that may have voting/dispositive power over those shares (Footnotes F3–F4). The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest.
• The sales were made pursuant to a Rule 10b5‑1 trading plan adopted Nov 11, 2025 (Footnote F1).
• Form 4 filed 2026-06-24 — reporting appears timely based on the transaction dates. The filing offers to provide per-price breakdowns on request (per weighted-average footnotes).

Context These are sales (S) — typically considered routine when executed under a pre-established 10b5‑1 plan and when shares are held by an institutional entity. The filing indicates the shares were sold by ForDyne (an entity jointly owned by Forbion funds) and that Kersten has roles in the management/advisory structure; this points to institutional-level disposition rather than a simple individual open‑market trade. No post-transaction shareholdings were provided in the excerpt.